Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-05-18
2010-11-23
Richter, Johann R (Department: 1616)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S279000, C424S405000, C424S602000, C424S641000, C424S646000, C424S677000, C424S681000, C424S682000
Reexamination Certificate
active
07838532
ABSTRACT:
Disclosed herein are formulations of fluoroquinolones suitable for aerosolization and use of such formulations for aerosol administration of fluoroquinolone antimicrobials for the treatment of pulmonary bacterial infections. In particular, inhaled levofloxacin specifically formulated and delivered for bacterial infections of the lungs is described. Methods include inhalation protocols and manufacturing procedures for production and use of the compositions described.
REFERENCES:
patent: 4730000 (1988-03-01), Chu
patent: 4844902 (1989-07-01), Grohe
patent: 4985557 (1991-01-01), Hayakawa et al.
patent: 5053407 (1991-10-01), Hayakawa et al.
patent: 5142046 (1992-08-01), Hayakawa et al.
patent: 5304559 (1994-04-01), Rozier
patent: 5334589 (1994-08-01), Al-Razzak et al.
patent: 5508269 (1996-04-01), Smith
patent: 5563155 (1996-10-01), Domagala et al.
patent: 5756506 (1998-05-01), Copeland et al.
patent: 6288080 (2001-09-01), Barsuhn et al.
patent: 6294178 (2001-09-01), Weinstein et al.
patent: 6333044 (2001-12-01), Santus et al.
patent: 6333045 (2001-12-01), Yasueda
patent: 6406880 (2002-06-01), Thornton
patent: 6468967 (2002-10-01), Oleson, Jr. et al.
patent: 6492328 (2002-12-01), Lehrer et al.
patent: 6503953 (2003-01-01), Vyden
patent: 6518239 (2003-02-01), Kuo et al.
patent: 6544555 (2003-04-01), Rudnic et al.
patent: 6576224 (2003-06-01), Osbakken et al.
patent: 6579854 (2003-06-01), Mitchell et al.
patent: 6605609 (2003-08-01), Barbachyn et al.
patent: 6608078 (2003-08-01), De Souza et al.
patent: 6663890 (2003-12-01), Rudnic et al.
patent: 6663891 (2003-12-01), Rudnic et al.
patent: 6664239 (2003-12-01), Mitchell et al.
patent: 6667042 (2003-12-01), Rudnic et al.
patent: 6667057 (2003-12-01), Rudnic et al.
patent: 6669948 (2003-12-01), Rudnic et al.
patent: 6689769 (2004-02-01), Gordeev et al.
patent: 6716819 (2004-04-01), Welsh et al.
patent: 6723341 (2004-04-01), Rudnic et al.
patent: 6730320 (2004-05-01), Rudnic et al.
patent: 6756369 (2004-06-01), Mitchell et al.
patent: 6806256 (2004-10-01), Ulrich
patent: 6835372 (2004-12-01), Kuo et al.
patent: 6838552 (2005-01-01), Mitchell et al.
patent: 6869965 (2005-03-01), Gordeev et al.
patent: 6878713 (2005-04-01), De Souza et al.
patent: 6884784 (2005-04-01), Mitchell et al.
patent: 6890526 (2005-05-01), Stratton et al.
patent: 6962151 (2005-11-01), Knoch
patent: 6987094 (2006-01-01), Malvolti et al.
patent: 7148404 (2006-12-01), Hogenhaug et al.
patent: 2001/0049366 (2001-12-01), Singh et al.
patent: 2002/0061281 (2002-05-01), Osbakken et al.
patent: 2002/0086867 (2002-07-01), Dubois
patent: 2002/0142050 (2002-10-01), Straub et al.
patent: 2002/0197212 (2002-12-01), Osbakken et al.
patent: 2003/0012814 (2003-01-01), Rudnic et al.
patent: 2003/0028025 (2003-02-01), Raghavan
patent: 2003/0032600 (2003-02-01), Ulrich et al.
patent: 2003/0078517 (2003-04-01), Kensey
patent: 2003/0138403 (2003-07-01), Drustrup
patent: 2003/0171340 (2003-09-01), Isbister
patent: 2003/0186894 (2003-10-01), Kuo et al.
patent: 2004/0009126 (2004-01-01), Pilkiewicz et al.
patent: 2004/0014750 (2004-01-01), Michaelis et al.
patent: 2004/0045546 (2004-03-01), Hirsh et al.
patent: 2004/0152701 (2004-08-01), Reddy et al.
patent: 2005/0036951 (2005-02-01), Henderson
patent: 2005/0106151 (2005-05-01), Shapiro
patent: 2005/0139211 (2005-06-01), Alston et al.
patent: 2005/0147567 (2005-07-01), Kuo et al.
patent: 2005/0235987 (2005-10-01), Smaldone et al.
patent: 2005/0260099 (2005-11-01), Xia et al.
patent: 2006/0003944 (2006-01-01), Glinka et al.
patent: 2006/0025355 (2006-02-01), Duddu et al.
patent: 2006/0223751 (2006-10-01), Mygind et al.
patent: 2006/0276463 (2006-12-01), Sharma et al.
patent: 2006/0276473 (2006-12-01), Bostion et al.
patent: 2006/0276483 (2006-12-01), Surber et al.
patent: 2006/0286574 (2006-12-01), Romesberg et al.
patent: 2007/0003753 (2007-01-01), Asgari
patent: 2007/0155715 (2007-07-01), van Duzer et al.
patent: 2007/0197548 (2007-08-01), Murthy
patent: 2009/0025713 (2009-01-01), Keller et al.
patent: 1 092 430 (2001-04-01), None
patent: 1 223 915 (2005-12-01), None
patent: WO 99/59566 (1999-11-01), None
patent: WO 00/18388 (2000-04-01), None
patent: WO 01/02024 (2001-01-01), None
patent: WO 02/18345 (2002-03-01), None
patent: WO 02/072102 (2002-09-01), None
patent: WO 03/075889 (2003-09-01), None
patent: WO 03/075889 (2003-09-01), None
patent: WO 2004/019912 (2004-03-01), None
patent: WO 2005/089738 (2005-09-01), None
patent: WO 2006/011051 (2006-02-01), None
patent: WO 2006/033713 (2006-03-01), None
patent: WO 2006/078925 (2006-07-01), None
patent: WO 2006/125132 (2006-11-01), None
patent: WO 2007/085057 (2007-08-01), None
patent: WO 2007/090123 (2007-08-01), None
patent: WO 2007/090646 (2007-08-01), None
patent: WO 2007/095156 (2007-08-01), None
patent: WO 2007/095187 (2007-08-01), None
patent: WO 2008/025560 (2008-03-01), None
“MPEX Pharmaceuticals Initiates Multi-Dose Clinical Trial in the U.S. with MP-376 in Patients with Cystic Fibrosis” Science Letter (2007) 2 pages.
Baker et al., “A Prodrug Approach Toward the Development of Water Soluble Fluoroquinolones and Structure-Activity Relationships of Quinoline-3-Carboxylic Acids”J. Med. Chem. (2004) 47:4693-4709.
Banerjee et al., “The treatment of respiratory pseudomonas infection in cystic fibrosis: what drug and which way?”Drugs(2000) 60(5):1053-64. (Abstract Only).
Battram et al., “In vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (indacaterol), a novel inhaled beta(2) adrenoceptor agonist with a 24-h duration of action”J Pharmacol Exp Ther. (2006) 317(2):762-70. (Abstract Only).
Benko et al., “Pharmacokinetics and pharmacodynamics of levofloxacin in critically ill patients with ventilator-associated pneumonia”International journal of antimicrobial agents(Netherlands) (2007) 30(2):162-8. (Abstract Only).
Berg, “Combination products are spotlighted at Drug/Device Summit”The BBI Newsletter(2005). (Abstract Only).
Brouillard et al., “Antibiotic selection and resistance issues with fluoroquinolones and doxycycline against bioterrorism agents”Pharmacotherapy(United States) (2006) 26(1):3-14. (Abstract Only).
Bryskier, “Bacillus anthracis and antibacterial agents”Clinical microbiology and infection—the official publication of the European Society of Clinical Microbiology and Infectious Diseases(France) (2002) 8(8):467-78. (Abstract Only).
Carratala et al., “Clinical experience in the management of community-acquired pneumonia: lessons from the use of fluoroquinolones”Clinical microbiology and infection—the official publication of the European Society of Clinical Microbiology and Infectious Diseases(France) (2006) 12(3):2-11. (Abstract Only).
DeRyke et al., “Pharmacodynamic target attainment of six beta-lactams and two fluoroquinolones againstPseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli, andKlebsiellaspecies collected from United States intensive care units in 2004”Pharmacotherapy(United States) (2007) 27(3):333-42. (Abstract Only).
Diakov et al., “The chemotherapeutic efficacy of ciprofloxacin and lomefloxacin in the inhalation method of infecting white mice with tularemia., Khimioterapevticheskaia effektivnost' tsiprofloksatsina i lomefloksatsina pri ingaliatsionnom sposobe zarazheniia tuliaremiei belykh myshei”Antibiotiki i khimioterapii a = Antibiotics and chemoterapy sic / Ministerstvo meditsinskoi i mikrobiologicheskoi promyshlennosti SSSR(Russia) (2000) 45(6):17-20. (Abstract Only).
Doring et al., “Antibiotic therapy againstPseudomonas aeruginosain cystic fibrosis: a European consensus” [comment in Eur Respir J. Oct. 2000;16(4):585-7],Eur Respir J. (2000) 16(4):749-67. (Abstract Only).
Drevensek et al., “Influence of Copper(II) and Magnesium(II) ions on the Ciprofloxacin Binding to DNA”,J.Inorg. Biochem. (2003) 96:407-415.
Drevensek et al., “X-Ray Crystallographic, NMR
Bostian Keith A.
Dudley Michael N.
Griffith David C.
Lomovskaya Olga
Surber Mark W.
Acevedo James H Alstrum
Knobbe Martens Olson & Bear LLP
Mpex Pharmaceuticals, Inc.
Richter Johann R
LandOfFree
Aerosolized fluoroquinolones and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Aerosolized fluoroquinolones and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aerosolized fluoroquinolones and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4209731